Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Insulin-treated diabetic cats frequently achieve transient remission. The glucagon-like peptide-1 receptor agonist, exenatide extended-release (exenatide-ER), preserves β cell function in people with type 2 diabetes mellitus (DM).
Objectives: Investigate the effect of exenatide-ER on the duration of diabetic remission in cats.
Animals: Twenty-two client-owned cats with recent diabetic remissions.
Methods: Placebo-controlled, single-blinded study. Cats were assigned randomly to receive exenatide-ER (0.13 mg/kg) or saline injection SC, once monthly for 2 years or until DM relapsed. Cats were fed low-carbohydrate diets; weight control was actively supervised. Paired t-tests and Mann-Whitney were used to compare pre- versus post-study characteristics within groups and between group outcomes, respectively.
Results: Treatment groups (placebo, N = 10; exenatide-ER, N = 12) were similar in age, sex, and body weight upon inclusion. Thirteen cats completed the 2-year study without diabetic relapse. Nine cats (placebo, n = 4; exenatide-ER, n = 5) exited prematurely. Three of these exited because of DM relapse (placebo: N = 1, day 212; exenatide-ER: N = 2, days 553 and 558). There was no difference in remission duration between treatments (placebo: 669 [121-721]; exenatide-ER: 662 [28-735] days, p = 0.9). Median body weight decreased in both groups at study exit (placebo: -0.6 kg [-1.3 to +0.3], p = 0.03; exenatide-ER: -0.2 kg [-1.2 to +0.5], p = 0.02). Hemoglobin A1c remained unchanged on exenatide-ER (-0.05% [-6.9 to +2.1]) but increased on placebo (+2.3% [-1.7 to +4.4]; p = 0.03).
Conclusions And Clinical Importance: Exenatide-ER contributed to the maintenance of glycemic control as reflected by hemoglobin A1c but did not affect remission duration. Management might have contributed to the extended remission duration.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921135 | PMC |
| http://dx.doi.org/10.1111/jvim.70069 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of duration of untreated psychosis on early clinical outcomes in drug-naïve schizophrenia: A 12-week follow-up study.
J Psychiatr Res
September 2025
Laboratory of Biological Psychiatry, Institute of Mental Health, Tianjin Anding Hospital, Mental Health Center of Tianjin Medical University, Tianjin, 300222, China. Electronic address:
Background: The duration of untreated psychosis (DUP) is a critical factor influencing long-term outcome in schizophrenia (SCZ). Its short-term effects during early treatment remain less well characterized.
Methods: We enrolled 300 drug-naïve SCZ patients, of whom 78 completed a 12-week evaluation with comprehensive clinical and functional assessments.
Serum levels of PECAM-1, ICAM-1, and VCAM-1 in patients with systemic lupus erythematosus: associations with disease activity and clinical features from a single-center study.
Rheumatol Int
September 2025
Clinical Department of Rheumatology, Immunology and Internal Medicine, University Hospital in Kraków, Jakubowskiego 2, Kraków, 30-688, Poland.
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by complex disturbances in both innate and adaptive immune responses, often leading to multi-organ involvement. One of the key features of SLE pathogenesis is endothelial dysfunction, which contributes to immune cell infiltration and vascular inflammation. In this context, adhesion molecules such as platelet endothelial cell adhesion molecule-1 (PECAM-1), intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) may reflect the degree of endothelial activation.
View Article and Find Full Text PDFThe impact of obesity and overweight on rheumatoid arthritis patients: real-world insights from a biologic and targeted synthetic DMARDs registry.
Rheumatol Int
September 2025
Department of Physical Medicine and Rehabilitaton, Ankara Bilkent City Hospital, Faculty of Medicine, Yıldırım Beyazıt University, Ankara, Türkiye, Turkey.
The Impact of Obesity and Overweight on Rheumatoid Arthritis Patients: Real-World Insights from a Biologic and Targeted Synthetic DMARDs Registry. The management of rheumatoid arthritis (RA) has advanced with biological and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs). However, obesity, a common comorbidity, impacts treatment and disease progression efficacy.
View Article and Find Full Text PDFDiscontinuation Reasons and Drug Survival of Dupilumab in Real-World Adult Atopic Dermatitis Patients in Three Healthcare Facilities in Tokyo and Yokohama (2018-2023).
J Dermatol
September 2025
Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
Dupilumab, a fully human IgG4 monoclonal antibody that inhibits interleukin (IL)-4 and IL-13 signaling by blocking the shared IL-4α subunit, is the first targeted systemic therapy for moderate-to-severe atopic dermatitis (AD). The drug was introduced in Japan in April 2018, along with other countries around the same time, leading to a dramatic improvement in patients' quality of life. This study aims to provide practical insights into the real-world use of dupilumab to support decision-making in drug selection and patient education.
View Article and Find Full Text PDFObservational analysis of biological remission as a treatment target for severe asthma: UK severe asthma registry.
J Allergy Clin Immunol Pract
September 2025
Wellcome Wolfson Institute for Experimental Medicine, Queen's University Belfast, UK; Belfast Health and Social Care Trust, Belfast, UK.
Background: The aim of biologic therapies in severe asthma is inhibition of T2 inflammatory pathways.
Objective: We hypothesized that patients who achieve complete suppression of IL-5 & IL4/IL13 pathways with biologic therapy (FeNO <20ppb & blood eosinophil count (BEC) <0.15x10ˆ9, 'biological remission') would have better outcomes than patients with incomplete suppression of T2 biology.